What's breaking now, across thousands of outlets.
The R2 is so far a success, and a lower-priced variant is on the way.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Business is booming for Vertiv Holdings (NYSE: VRT).
Key PointsAbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win.
Revenue growth is accelerating, with the good times forecasted to last several years.
Lucid (NASDAQ: LCID) signs another major deal with huge implications for shareholders.
